statnews.com·Mar 18, 2026
The article discusses a Huntington's researcher, Ed Wild, who cautiously comments on the ongoing dispute between UniQure and the FDA regarding an experimental gene therapy for Huntington's disease, which previously showed promising results in slowing disease progression.
The most valuable insight for you is the recent UniQure-FDA fray regarding their gene therapy for Huntington's disease, which previously showed promising results by slowing disease progression by 75%. This ongoing regulatory challenge could signal potential delays or hurdles in gene therapy advancements, making it critical to monitor for future investment and collaboration opportunities in gene therapy and related biotech ventures.